Novartis AG Stock News

Sandoz (OTCMKT: SDZNY ) stock is a hot topic among traders on Wednesday as the company starts trading after a spinoff. Let's get into everything investors need to know about Sandoz below!

Swiss drugs giant Novartis AG has completed the spin-off of its generics business Sandoz, which made an underpowered stock market debut. From an IPO price of 24 Swiss Francs, the stock drifted down t

Novartis has completed the planned spin-off of its generics and biosimilars business, Sandoz, which will begin trading on the SIX Swiss Exchange on Wednesday.

Novartis has completed the planned spin-off of its generics and biosimilars business Sandoz , the Swiss drugmaker said in a statement on Wednesday.

Novartis' (NVS) phase III study on pipeline candidate iptacopan in patients with IgAN shows superiority versus placebo in proteinuria reduction.

Novartis CEO Vas Narasimhan joins 'Squawk on the Street' to discuss the company's new spin-off Sandoz, what a pure-play core pharmaceutical company means, and the idea of M&A to boost the company's gr

Vas Narasimhan, CEO at Novartis, discusses the company's 100% spin off of Sandoz, its generic and biosimilar medicines business, and what the deal means for shareholders.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Novartis AG is considering selling a part of its radiopharmaceuticals business, Bloomberg News reported on Tuesday, citing people with knowledge of the matter.

The lengthy negotiation process with Medicare won't end until August 2024, with reduced prices going into effect in January 2026.

All the drugmakers that make the 10 prescription medicines subject to the first-ever price negotiations for the U.S. Medicare health program, including Amgen and Novartis , said they signed on to part

Novartis' (NVS) Sandoz broadens its biosimilar portfolio with Tyruko's approval, a biosimilar of the multiple sclerosis drug Tysabri in the EU.

Novartis' core EPS payout ratio is poised to come in at around 51% in 2023. The Swiss drugmaker grew at a solid clip in the first half of this year. The company enjoys an AA- credit rating from rating

Novartis' (NVS) radioligand therapy Lutathera reports statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors

Morgan Stanley (NYSE:MS) expects the EU biopharma sector to offer a safe haven from weakening growth/higher real yields. “Whilst we continue to favour growth/innovation narratives in biopharma over